Treatment of vulvar intraepithelial neoplasia using topical imiquimod 5% cream in a genitourinary medicine clinic setting.
In the last five years, options for the treatment of vulvar intraepithelial neoplasia (VIN) have come to include the use of the immune response modifier imiquimod, following case reports of its efficacy in the USA and Europe. Despite topical imiquimod 5% cream being frequently prescribed for the treatment of ano-genital warts, there are no reports of it being used for the treatment of VIN in a genitourinary medicine setting. In this case report self-administered topical imiquimod 5% cream proved an effective treatment for undifferentiated VIN2/3 and should be considered as an alternative therapy in a genitourinary medicine setting.
McQuillan
O
O
Department of Genitourinary Medicine, Bolton Centre for Sexual Health, Royal Bolton Hospital, Minerva Road, Bolton, Lancashire BL4 0JR, UK. orla.mcquillan@CMMC.nhs.uk
Morgan
E
E
D000287:Administration, Topical; D000328:Adult; D000554:Ambulatory Care Facilities; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D000077271:Imiquimod; D014846:Vulvar Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod